Becton Dickinson (BDX) Position Trimmed by Haverford Financial Services Inc.

Haverford Financial Services Inc. lowered its stake in Becton Dickinson (NYSE:BDX) by 1.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,833 shares of the medical instruments supplier’s stock after selling 290 shares during the period. Becton Dickinson accounts for approximately 2.4% of Haverford Financial Services Inc.’s holdings, making the stock its 20th biggest holding. Haverford Financial Services Inc.’s holdings in Becton Dickinson were worth $6,248,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in BDX. Legacy Advisors LLC boosted its holdings in Becton Dickinson by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares in the last quarter. Amica Retiree Medical Trust lifted its position in Becton Dickinson by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 390 shares during the period. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson during the fourth quarter valued at $109,000. FTB Advisors Inc. lifted its position in Becton Dickinson by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 290 shares during the period. Finally, Advisors Preferred LLC purchased a new position in Becton Dickinson during the fourth quarter valued at $126,000. Institutional investors and hedge funds own 84.02% of the company’s stock.

Becton Dickinson opened at $224.22 on Friday, according to Marketbeat. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $60.09 billion, a PE ratio of 22.51, a P/E/G ratio of 1.56 and a beta of 1.15. Becton Dickinson has a 1 year low of $223.76 and a 1 year high of $224.74.

Becton Dickinson (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.02. The firm had revenue of $4.22 billion during the quarter, compared to analyst estimates of $4.12 billion. Becton Dickinson had a positive return on equity of 14.27% and a negative net margin of 0.46%. Becton Dickinson’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.30 EPS. sell-side analysts forecast that Becton Dickinson will post 10.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s dividend payout ratio is presently 31.65%.

Several equities analysts have commented on BDX shares. Citigroup raised Becton Dickinson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $237.00 to $251.00 in a research report on Tuesday, April 10th. Zacks Investment Research raised Becton Dickinson from a “hold” rating to a “buy” rating and set a $259.00 price objective for the company in a research report on Friday, January 19th. Morgan Stanley raised their price objective on Becton Dickinson from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. ValuEngine raised Becton Dickinson from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Finally, Bank of America reissued a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson in a research report on Friday, January 19th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $241.19.

In related news, Director David F. Melcher purchased 500 shares of the stock in a transaction dated Monday, May 7th. The stock was purchased at an average price of $225.07 per share, with a total value of $112,535.00. Following the transaction, the director now directly owns 2,728 shares in the company, valued at $613,990.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Nabil Shabshab sold 10,209 shares of Becton Dickinson stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $226.10, for a total value of $2,308,254.90. Following the completion of the transaction, the executive vice president now directly owns 12,476 shares of the company’s stock, valued at approximately $2,820,823.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,656 shares of company stock valued at $4,892,092. 1.00% of the stock is owned by insiders.

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson (NYSE:BDX)

Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply